Nanotechnology applications in surgical oncology.

Surgery is currently the most effective and widely used procedure in treating human cancers, and the single most important predictor of patient survival is a complete surgical resection. Major opportunities exist to develop new and innovative technologies that could help the surgeon to delineate tumor margins, to identify residual tumor cells and micrometastases, and to determine if the tumor has been completely removed. Here we discuss recent advances in nanotechnology and optical instrumentation, and how these advances can be integrated for applications in surgical oncology. A fundamental rationale is that nanometer-sized particles such as quantum dots and colloidal gold have functional and structural properties that are not available from either discrete molecules or bulk materials. When conjugated with targeting ligands such as monoclonal antibodies, peptides, or small molecules, these nanoparticles can be used to target malignant tumor cells and tumor microenvironments with high specificity and affinity. In the "mesoscopic" size range of 10-100 nm, nanoparticles also have large surface areas for conjugating to multiple diagnostic and therapeutic agents, opening new possibilities in integrated cancer imaging and therapy.

[1]  P. Alivisatos.  The use of nanocrystals in biological detection , 2004, Nature Biotechnology.

[2]  N. Powe,et al.  The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. , 1998, Annals of surgery.

[3]  R. Shukla,et al.  Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[4]  Merrick I Ross,et al.  Positive surgical margins and ipsilateral breast tumor recurrence predict disease‐specific survival after breast‐conserving therapy , 2003, Cancer.

[5]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[6]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Hak Soo Choi,et al.  Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node Mapping , 2006, Annals of Surgical Oncology.

[8]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[9]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[10]  L. Cohn,et al.  Sentinel Lymph Node Mapping of the Gastrointestinal Tract by Using Invisible Light , 2006, Annals of Surgical Oncology.

[11]  Vladimir P Torchilin,et al.  Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo , 2005, Nature Medicine.

[12]  L. Cohn,et al.  Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. , 2005, The Journal of thoracic and cardiovascular surgery.

[13]  J. Wind,et al.  Residual disease at the bronchial stump after curative resection for lung cancer. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  M. Soloway,et al.  Intraoperative T staging in radical retropubic prostatectomy: is it reliable? , 2001, Urology.

[15]  Andreas Kirschbaum,et al.  Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for segmentectomy. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  Kaiyang Li,et al.  Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. , 2007, Journal of biomedical optics.

[17]  Noriaki Ohuchi,et al.  In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. , 2007, Cancer research.

[18]  Hisataka Kobayashi,et al.  Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. , 2009, Journal of biomedical optics.

[19]  Ralph Weissleder,et al.  A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. , 2003, Cancer research.

[20]  Sanjiv S Gambhir,et al.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.

[21]  Giulio F. Paciotti,et al.  Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors , 2006 .

[22]  Judith Sandbank,et al.  A device for real-time, intraoperative margin assessment in breast-conservation surgery. , 2007, American journal of surgery.

[23]  Steven R. Emory,et al.  Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering , 1997, Science.

[24]  Sharmeela Kaushal,et al.  Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer , 2008, Journal of Gastrointestinal Surgery.

[25]  S. Schnitt,et al.  Understanding the distribution of cancer within the breast is important for optimizing breast‐conserving treatment , 1995, Cancer.

[26]  Marcelino Bernardo,et al.  An enzymatically activated fluorescence probe for targeted tumor imaging. , 2007, Journal of the American Chemical Society.

[27]  G A ANDREWS,et al.  The distribution and radiation effects of intravenously administered colloidal Au198 in man , 1954, Cancer.

[28]  M. Pirenne,et al.  Accuracy and Sensitivity of the Human Eye , 1952, Nature.

[29]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[30]  H. Dai,et al.  In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.

[31]  R. Mansel,et al.  Can preoperative factors predict for residual malignancy after breast biopsy for invasive cancer? , 1995, Annals of the Royal College of Surgeons of England.

[32]  Marcelino Bernardo,et al.  A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. , 2007, Cancer research.

[33]  May D. Wang,et al.  Biomedical Nanotechnology With Bioinformatics—The Promise and Current Progress , 2007 .

[34]  F. Marshall,et al.  In vivo molecular and cellular imaging with quantum dots. , 2005, Current opinion in biotechnology.

[35]  James R Heath,et al.  Nanotechnology and cancer. , 2008, Annual review of medicine.

[36]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[37]  I Ihse,et al.  Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.

[38]  J. Frangioni,et al.  An Operational Near-Infrared Fluorescence Imaging System Prototype for Large Animal Surgery , 2003, Technology in cancer research & treatment.

[39]  L. Cohn,et al.  Sentinel lymph node mapping of the pleural space. , 2005, Chest.

[40]  Tristan Barrett,et al.  Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes , 2009, Nature Medicine.

[41]  Nina M. Muñoz,et al.  Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. , 2007, Cancer research.

[42]  D R Walker,et al.  Fate of patients with residual tumour at the bronchial resection margin. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[43]  Hisataka Kobayashi,et al.  Multicolor in vivo targeted imaging to guide real‐time surgery of HER2‐positive micrometastases in a two‐tumor coincident model of ovarian cancer , 2009, Cancer science.

[44]  John V. Frangioni,et al.  Organic Alternatives to Quantum Dots for Intraoperative Near-Infrared Fluorescent Sentinel Lymph Node Mapping , 2005, Molecular imaging.

[45]  May D. Wang,et al.  Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. , 2009, Trends in biotechnology.

[46]  Osman Muhammad,et al.  QUANTUM DOTS ARE PHAGOCYTIZED BY MACROPHAGES AND COLOCALIZE WITH EXPERIMENTAL GLIOMAS , 2007, Neurosurgery.

[47]  J. D. Payne,et al.  Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice , 2007 .

[48]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[49]  R. Dasari,et al.  Single Molecule Detection Using Surface-Enhanced Raman Scattering (SERS) , 1997 .

[50]  R K Jain,et al.  Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[51]  John V Frangioni,et al.  Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. , 2005, The Annals of thoracic surgery.

[52]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Mihaljevic,et al.  Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping , 2004, Nature Biotechnology.

[54]  James A J Fitzpatrick,et al.  Sentinel lymph node imaging using quantum dots in mouse tumor models. , 2007, Bioconjugate chemistry.

[55]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[56]  B Merchant,et al.  Gold, the noble metal and the paradoxes of its toxicology. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[57]  Sharmeela Kaushal,et al.  Imaging of Primary and Metastatic Pancreatic Cancer Using a Fluorophore-Conjugated Anti-CA19-9 Antibody for Surgical Navigation , 2008, World Journal of Surgery.

[58]  D. Fraker,et al.  Sampling of grossly benign breast reexcisions: a multidisciplinary approach to assessing adequacy. , 1999, The American journal of surgical pathology.

[59]  John A. Cowan,et al.  Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? , 2003, The Annals of thoracic surgery.

[60]  Hisataka Kobayashi,et al.  Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. , 2009, Molecular pharmaceutics.

[61]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.